查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1226716

臨床障礙治療的全球市場:現狀分析、預測(2022年～2028年)

Clinical Disorder Treatment Market: Current Analysis and Forecast (2022-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 154 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球臨床障礙治療的市場規模，與精神、心理疾病的盛行率同樣，青春期的藥物依賴症全球增加，以約6％穩定成長。還有許多醫院，診所，醫療機關，對一般大眾實施臨床疾病恰當治療方法相關教育宣傳活動，預計不久的將來，有帶給市場很大成長的可能性。

本報告提供全球臨床障礙治療市場相關調查分析，各市場區隔、各地區的市場洞察，市場動態，市場趨勢，競爭情形，企業簡介等系統性資訊。

目錄

第1章 市場簡介

第2章 調查手法、前提條件

第3章 市場概要

第4章 摘要整理

第5章 COVID-19對臨床障礙市場的影響

第6章 臨床障礙市場收益(2020年～2028年)

第7章 市場洞察:各類藥物

  • 抗憂鬱症藥
  • 抗痙攣藥
  • 抗焦慮藥
  • 非典型抗精神病藥物
  • 去甲腎上腺素促效劑

第8章 市場洞察:各症狀

  • 不安
  • 打

第9章 市場洞察:各藥物銷售管道

  • 院內藥局
  • 零售藥局
  • 線上藥局

第10章 市場洞察:各地區

  • 北美
    • 美國
    • 加拿大
    • 其他北美
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他地區

第11章 臨床障礙:市場動態

  • 推動市場要素
  • 市場課題
  • 影響分析

第12章 臨床障礙:市場機會

第13章 臨床障礙:市場趨勢

第14章 需求側、供給側的分析

  • 需求面分析
  • 供給側分析

第15章 價值鏈分析

第16章 價格分析

第17章 策略性舉措

第18章 競爭模式

  • 競爭情形
    • 波特的五力分析

第19章 企業概要

  • Universal Health Services, Inc
  • CareTech Holdings Plc
  • Behavioral Health Network, Inc
  • Pfizer Inc
  • GSK Plc
  • Eli Lilly and Company
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • VistaGen Therapeutics, Inc

第20章 免責聲明

簡介目錄
Product Code: UMME211603

Clinical Disorder treatment are focused on the diagnosis and treatment of psychiatric and psychological disorders. The main areas focus on mood disorders, anxiety disorders, obesity and eating disorders, addictions, and psychosomatic disorders. This illness can affect anyone, and of any age. This disorder is treatable. According to a statistical report by Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), 264 million people were affected by depression, whereas, dementia affected nearly 50 million people globally. This is in turn projected to offer abundant growth opportunities.

The clinical disorder treatment market is expected to grow at a steady rate of around 6% owing to the increasing use of adolescent substance addiction is on the rise globally, as is the prevalence of mental and psychological illnesses. Additionally, a lot of hospitals, clinics, and healthcare organizations are running campaigns to educate the general people about the proper course of treatment for clinical diseases. In turn, this is anticipated to provide the market with a wealth of growth potential in the near future.

Based on drug class, the market is segmented into antidepressants, anticonvulsants, anxiolytics, atypical antipsychotics, and noradrenergic agents. The antidepressants category held a significant share in 2020. An increasing number of candidates and product approvals of antidepressants will boost the market segment growth in the future due to rising hospital visits. Recently, the Food and Drug Administration (FDA) authorized two brand-new antidepressants that offer innovative methods for treating depression: esketamine and brexanolone.

Based on the indication, the market is categorized into anxiety and depression. This is mainly due to the influence of COVID-19 on the world which has been unparalleled and astounding, with increased demand shocks for anxiety disorders and depression treatment goods throughout all regions during the pandemic. During this time people are largely exposed to anxiety disorder. In addition, collaborative efforts by healthcare companies, NGOs, and government initiatives spreading awareness have become another factor in demand.

Based on the drug distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is predicted to grow at the fastest rate among all medication distribution channels over the course of the projection year.

For a better understanding of the market adoption of the clinical disorder treatment, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The market in North America is anticipated to gain the major proportion throughout the projection period owing to the region's high healthcare spending and growing awareness of the signs and symptoms of clinical illnesses. Additionally, in the APAC region it is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to growing incidences of substance abuse among teenagers and adults, in the countries like India and China. In 2019, South Asia regions witness approximately 30 million people is exposed to cannabis and 22 million people consuming opioids. In the upcoming years, it is also anticipated that the region's industry will increase due to the strong presence of key market players.

Some of the major players operating in the market include: Universal Health Services Inc, CareTech Holdings plc, Behavioral Health Network Inc, Pfizer Inc, GSK plc, Eli Lilly and Company, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc and VistaGen Therapeutics Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Clinical Disorder Treatment Market
  • 2.2. Research Methodology of the Clinical Disorder Treatment Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CLINICAL DISORDER MARKET

6 CLINICAL DISORDER MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG CLASS

  • 7.1. Antidepressants
  • 7.2. Anticonvulsants
  • 7.3. Anxiolytics
  • 7.4. Atypical Antipsychotics
  • 7.5. Noradrenergic agents

8 MARKET INSIGHTS BY INDICATION

  • 8.1. Anxiety
  • 8.2. Depression

9 MARKET INSIGHTS BY DRUG DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacy
  • 9.2. Retail Pharmacy
  • 9.3. Online Pharmacy

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. USA
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 CLINICAL DISORDER MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 CLINICAL DISORDER MARKET OPPORTUNITIES

13 CLINICAL DISORDER MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INITIATIVES

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. Universal Health Services, Inc
  • 19.2. CareTech Holdings Plc
  • 19.3. Behavioral Health Network, Inc
  • 19.4. Pfizer Inc
  • 19.5. GSK Plc
  • 19.6. Eli Lilly and Company
  • 19.7. AstraZeneca Plc
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Johnson & Johnson Services, Inc
  • 19.10. VistaGen Therapeutics, Inc

20 DISCLAIMER